Patients with MS-AF were more likely to receive digoxin (p = 0.027) and diuretics (p = 0.001), while patients with NVAF were more likely to receive angiotensin-converting enzyme (ACE) inhibitors (p = 0.001). This evidence concerns the gene ACE and atrial fibrillation.